Purdue Pharmaceuticals, the maker of the opioid painkiller OxyContin, said it would no longer actively market opioid products — a major about-face for a company increasingly viewed as a principal culprit in the country’s addiction and overdose crisis.
The company said it is reducing its sales staff by more than half, and that its remaining salespeople will no longer visit doctor’s offices to push their product. Instead, the company said it will direct prescribers to materials published by the Centers for Disease Control and Prevention and the office of the U.S. surgeon general.
About the Authors Reprints
